CA3235971A1 - Methods and materials for expanding tumor infiltrating gamma-delta t cells - Google Patents

Methods and materials for expanding tumor infiltrating gamma-delta t cells Download PDF

Info

Publication number
CA3235971A1
CA3235971A1 CA3235971A CA3235971A CA3235971A1 CA 3235971 A1 CA3235971 A1 CA 3235971A1 CA 3235971 A CA3235971 A CA 3235971A CA 3235971 A CA3235971 A CA 3235971A CA 3235971 A1 CA3235971 A1 CA 3235971A1
Authority
CA
Canada
Prior art keywords
cells
cell population
percent
tcr
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235971A
Other languages
English (en)
French (fr)
Inventor
Michael T. Lotze
Pranav Murthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CA3235971A1 publication Critical patent/CA3235971A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CA3235971A 2021-10-20 2022-10-14 Methods and materials for expanding tumor infiltrating gamma-delta t cells Pending CA3235971A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257805P 2021-10-20 2021-10-20
US63/257,805 2021-10-20
PCT/US2022/046745 WO2023069322A1 (en) 2021-10-20 2022-10-14 Methods and materials for expanding tumor infiltrating gamma-delta t cells

Publications (1)

Publication Number Publication Date
CA3235971A1 true CA3235971A1 (en) 2023-04-27

Family

ID=85980818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235971A Pending CA3235971A1 (en) 2021-10-20 2022-10-14 Methods and materials for expanding tumor infiltrating gamma-delta t cells

Country Status (5)

Country Link
US (1) US20230117388A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419118A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539088A (cg-RX-API-DMAC7.html)
CA (1) CA3235971A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023069322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025082502A1 (en) * 2023-10-18 2025-04-24 Nanjing Legend Biotech Co., Ltd. Pan t cells and methods of manufacturing of the same
ES3034332B2 (es) * 2025-05-21 2026-05-08 Univ Madrid Complutense Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336302T3 (es) * 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
CA3082818A1 (en) * 2017-11-15 2019-05-23 Adicet Bio Inc. Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof
EP3927353A4 (en) * 2019-02-24 2022-11-23 Gamida-Cell Ltd. METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY
CA3148588A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations

Also Published As

Publication number Publication date
US20230117388A1 (en) 2023-04-20
JP2024539088A (ja) 2024-10-28
WO2023069322A9 (en) 2023-08-10
EP4419118A1 (en) 2024-08-28
EP4419118A4 (en) 2025-04-30
WO2023069322A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP7860161B2 (ja) 非造血組織常在性γδ T細胞の増幅および該細胞の使用
US11905529B2 (en) Method of enhancing persistence of adoptively infused T cells
Vacca et al. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
JP7373543B2 (ja) 2型自然リンパ球細胞、インターロイキン33、及び/またはインターフェロン誘導性タンパク質44による癌免疫の調節
EP3200818B1 (en) Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
ES2980469T3 (es) Métodos para producir linfocitos T autólogos útiles para tratar cánceres y composiciones de los mismos
CN103635573A (zh) 包含γδT细胞的淋巴细胞系、其组合物及生产方法
JP2023540361A (ja) 養子細胞療法に対する応答に関連するt細胞表現型
US20230138309A1 (en) Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy
US20230117388A1 (en) Methods and materials for expanding tumor infiltrating gamma-delta t cells
de Mey et al. An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8+ T cells
US20210290672A1 (en) Regulation of tumor-associated t cells
JP2023516538A (ja) Ucart細胞を精製する方法及び応用
Naizir et al. TOX drives CD4+ TH1 effector function, antitumor immunity and autoimmune pathology
US20250333699A1 (en) Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells
CN114599784A (zh) 具有cd45ra+和ccr7+的细胞表面标志物的t细胞的制备方法
US20240150711A1 (en) Personalized redirection and reprogramming of t cells for precise targeting of tumors
US20250041344A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
RU2808595C1 (ru) Способ получения культуры лимфоцитов, обогащенных опухоль-специфичными клонами т-лимфоцитов, и клеточные культуры, полученные с использованием указанного способа
Prokhnevska CD8 T cell activation in cancer is comprised of two distinct phases
EP4538366A1 (en) Enhancing lineage stability of therapeutic regulatory t cell products
Han Profiling Durable Anti-Tumor Memory T Cell Responses in Long-Term Melanoma Survivors
Venkatesh B Cell Leukemia Elicits a Suppressive Tr1-CD4+ T Cell Response That Can Be Reprogrammed With PDL1-Blockade
JP7524210B2 (ja) Cd28 t細胞培養物、組成、およびその使用方法
Yao Reshape of CAR-T cells by overexpression of TCF-1

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241014

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241014

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241014

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819